Clinical Education
Melasma in Darker Skin: Why 1064 nm Matters
In melanin-rich skin, wavelength selection is central to melasma treatment strategy. Because 1064 nm has lower relative absorption by epidermal melanin than 755 nm, it offers a more favorable optical profile when epidermal melanin sparing is a priority.
Key facts
The 1064 nm wavelength is less absorbed by epidermal melanin than shorter wavelengths, which may help reduce the risk of pigment-related side effects in darker skin tones (Fitzpatrick IV–VI).
Published studies report that 1064 nm picosecond laser can improve melasma, though results vary and may be comparable to established treatments; outcomes depend on individual factors and a course of treatment.
Treating melasma in richly pigmented skin requires precision, not fear
Fitzpatrick IV–VI skin contains more baseline epidermal melanin. That matters because epidermal melanin competes for incoming laser energy before that energy ever reaches the intended target.
So when a device is being evaluated for darker, pigment-prone skin, one of the first questions should be:
What wavelength am I actually putting through the epidermis?
Not simply:
Is the device picosecond?
Pulse duration matters. But wavelength remains fundamental.
755 nm and 1064 nm are not interchangeable
755 nm alexandrite energy has stronger interaction with melanin than 1064 nm Nd:YAG.
That difference is useful in some applications. In melanin-rich skin, however, greater epidermal melanin interaction can narrow the treatment window between the intended target and the surrounding pigmented epidermis.
By comparison, 1064 nm penetrates more deeply with lower relative absorption by epidermal melanin. That is why 1064 nm is such an important wavelength when treatment planning prioritizes epidermal melanin sparing.
This is not a manufacturer-specific claim. It is an optical property of the wavelength.
And it leads to an important clinical principle:
For Fitzpatrick IV–VI melasma, 1064 nm provides the more logical wavelength foundation when minimizing unnecessary epidermal melanin interaction is a priority.
That statement is not the same as saying every 1064 nm protocol is automatically safe, or that 755 nm can never be used. It means wavelength selection should be grounded in skin biology, not marketing shorthand.
The melasma literature reflects the wavelength difference
A 2023 systematic review and meta-analysis of six randomized controlled trials evaluated picosecond treatment at multiple wavelengths. In subgroup analysis, 1064 nm picosecond treatment significantly reduced MASI/mMASI, with no significant side effects reported in that subgroup. The 755 nm subgroup did not significantly outperform topical depigmenting agents and reported post-inflammatory hyperpigmentation. View the PubMed record.
A separate 2023 randomized, controlled, assessor-blinded study compared non-fractional 1064 nm picosecond Nd:YAG, 755 nm picosecond alexandrite, and 2% hydroquinone in 60 patients with Fitzpatrick III–IV skin. The 1064 nm group produced the greatest MASI reduction, while the 755 nm group performed similarly to hydroquinone. View the published trial.
Those studies do not prove every 1064 nm device will outperform every 755 nm device. They do show why it is scientifically weak to collapse the conversation into “picosecond = picosecond.”
The wavelength still matters.
What about Fitzpatrick V–VI specifically?
This is where the language needs to stay accurate.
The strongest head-to-head randomized melasma trials comparing 755 nm and 1064 nm have primarily enrolled Fitzpatrick III–IV patients. That means direct randomized evidence in Fitzpatrick V–VI is still limited.
But the wavelength rationale does not disappear because the evidence base is incomplete. If anything, higher epidermal melanin makes the optical distinction more clinically relevant, not less.
That gives us a strong but defensible position:
1064 nm offers a more favorable wavelength profile for treatment planning in melanin-rich skin because it reduces competing epidermal melanin interaction relative to 755 nm.
Then provider technique, fluence, spot size, cumulative energy, treatment interval, and patient selection determine how that wavelength is actually used.
Why Pro 1 Pico starts with 1064 nm
The Pro 1 Pico is built around 1064 nm as its primary wavelength.
For practices treating diverse skin tones, that matters because the platform does not require the provider to begin with a shorter, more melanin-absorptive wavelength and then work around that limitation.
It gives the provider multiple 1064 nm treatment behaviors from the same system:
- 500 ps picosecond delivery for pigment-focused photoacoustic treatment.
- PTP dual-pulse delivery as an additional picosecond treatment option.
- Long-pulse 1064 nm as a separate photothermal pathway for appropriate vascular and thermal targets.
- A broader treatment menu beyond melasma, including pigment, tattoos, PMU, redness, visible vessels, skin quality, scar and texture remodeling, and hair-restoration protocols.
That is the difference between buying a laser because it has a melasma claim and buying a platform because its wavelength architecture makes sense for the patient population you actually treat.
Strong claims should come with strong reasoning
It is easy to put “all skin types” on a marketing page.
A better standard is to explain why a wavelength is selected for melanin-rich skin and where the evidence is strong or still developing.
For Fitzpatrick IV–VI melasma, the commercially useful message is also the scientifically useful one:
1064 nm first. Because wavelength matters.
Continue reading
- Melasma Treatment: Why Wavelength and Treatment Strategy Matter
- Pro 1 Pico for Melasma
- 1064 nm vs 532 nm Picosecond Laser
- Why Melasma Requires a Conservative Energy Strategy
Treatment suitability and parameters remain provider-directed. Results vary, and melasma may recur.
Technologies covered
Related devices
Related applications
FAQs
Why is 1064 nm important for Fitzpatrick IV–VI melasma?
Higher baseline epidermal melanin increases competition for incoming laser energy. Compared with 755 nm, 1064 nm has lower relative epidermal melanin absorption, giving it a more favorable optical profile when melanin sparing is important.
Does that mean 755 nm can never be used for melasma?
No. It means 755 nm and 1064 nm should not be treated as interchangeable. 755 nm has stronger melanin interaction, so wavelength choice, parameters, skin type, and treatment strategy all matter.
Is there melasma evidence comparing 755 nm and 1064 nm?
Yes. A 2023 meta-analysis of randomized trials favored the 1064 nm subgroup, and a separate randomized Fitzpatrick III–IV trial found greater MASI reduction with 1064 nm picosecond Nd:YAG than with 755 nm picosecond alexandrite or hydroquinone.
Can you say 1064 nm is proven safe for every Fitzpatrick V–VI melasma patient?
No. The wavelength rationale is strong, but direct randomized melasma data in Fitzpatrick V–VI remain limited. Treatment still depends on patient selection, parameters, cumulative exposure, and provider judgment.